Akari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1

Reuters

2025/11/10

Akari <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1

Akari Therapeutics plc has announced the initiation of IND-enabling studies for its lead antibody-drug conjugate $(ADC)$ candidate, AKTX-101, which targets the Trop2 receptor on cancer cells using a proprietary linker and a novel PH1 payload. The PH1 payload is designed to disrupt the spliceosome and has demonstrated a unique preclinical efficacy and safety profile. Results from preclinical studies, including data showing that a Trastuzumab PH1 combination with anti-PD1 produced a statistically significantly higher rate of complete responses compared to Kadcyla® + anti-PD1 (74% vs 42%, p<0.05), were recently presented at the 40th Annual SITC Meeting. Additional immune mechanism-of-action data for the PH1 payload were also presented at this conference. Akari plans to advance AKTX-101 into clinical trials in the near future and will host a webcast to discuss the presented data on November 18, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582874803"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582874803\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582874803?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582874803","market":"us","top_or_hot":-1,"title":"Akari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akari <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akari Therapeutics plc has announced the initiation of IND-enabling studies for its lead antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> candidate, AKTX-101, which targets the Trop2 receptor on cancer cells using a proprietary linker and a novel PH1 payload. The PH1 payload is designed to disrupt the spliceosome and has demonstrated a unique preclinical efficacy and safety profile. Results from preclinical studies, including data showing that a Trastuzumab PH1 combination with anti-PD1 produced a statistically significantly higher rate of complete responses compared to Kadcyla® + anti-PD1 (74% vs 42%, p&lt;0.05), were recently presented at the 40th Annual SITC Meeting. Additional immune mechanism-of-action data for the PH1 payload were also presented at this conference. Akari plans to advance AKTX-101 into clinical trials in the near future and will host a webcast to discuss the presented data on November 18, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akari <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akari Therapeutics plc has announced the initiation of IND-enabling studies for its lead antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> candidate, AKTX-101, which targets the Trop2 receptor on cancer cells using a proprietary linker and a novel PH1 payload. The PH1 payload is designed to disrupt the spliceosome and has demonstrated a unique preclinical efficacy and safety profile. Results from preclinical studies, including data showing that a Trastuzumab PH1 combination with anti-PD1 produced a statistically significantly higher rate of complete responses compared to Kadcyla® + anti-PD1 (74% vs 42%, p&lt;0.05), were recently presented at the 40th Annual SITC Meeting. Additional immune mechanism-of-action data for the PH1 payload were also presented at this conference. Akari plans to advance AKTX-101 into clinical trials in the near future and will host a webcast to discuss the presented data on November 18, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL2x5xyp:1","article_id":"2582874803","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582874803","pubTimestamp":1762781759,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Akari Therapeutics plc has announced the initiation of IND-enabling studies for its lead antibody-drug conjugate  candidate, AKTX-101, which targets the Trop2 receptor on cancer cells using a proprietary linker and a novel PH1 payload. The PH1 payload is designed to disrupt the spliceosome and has demonstrated a unique preclinical efficacy and safety profile. Results from preclinical studies, including data showing that a Trastuzumab PH1 combination with anti-PD1 produced a statistically significantly higher rate of complete responses compared to Kadcyla + anti-PD1 , were recently presented at the 40th Annual SITC Meeting. Additional immune mechanism-of-action data for the PH1 payload were also presented at this conference. Akari plans to advance AKTX-101 into clinical trials in the near future and will host a webcast to discuss the presented data on November 18, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","AKTX":"Akari Therapeutics PLC"},"translate_title":"Akari Therapeutics公布了新型剪接靶向ADC有效负载PH1的有希望的临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKTX":0.9},"content_text":"Akari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1\n    \n\n        Akari Therapeutics plc has announced the initiation of IND-enabling studies for its lead antibody-drug conjugate $(ADC)$ candidate, AKTX-101, which targets the Trop2 receptor on cancer cells using a proprietary linker and a novel PH1 payload. The PH1 payload is designed to disrupt the spliceosome and has demonstrated a unique preclinical efficacy and safety profile. Results from preclinical studies, including data showing that a Trastuzumab PH1 combination with anti-PD1 produced a statistically significantly higher rate of complete responses compared to Kadcyla® + anti-PD1 (74% vs 42%, p<0.05), were recently presented at the 40th Annual SITC Meeting. Additional immune mechanism-of-action data for the PH1 payload were also presented at this conference. Akari plans to advance AKTX-101 into clinical trials in the near future and will host a webcast to discuss the presented data on November 18, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}